E A M Heijnsdijk

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. pmc Breast density as indicator for the use of mammography or MRI to screen women with familial risk for breast cancer (FaMRIsc): a multicentre randomized controlled trial
    Sepideh Saadatmand
    Department of Surgery, Erasmus University Medical Centre, Rotterdam, Netherlands
    BMC Cancer 12:440. 2012
  2. doi request reprint Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combined
    Eveline A M Heijnsdijk
    Department of Public Health, Erasmus MC, Rotterdam, The Netherlands
    Cancer Epidemiol Biomarkers Prev 21:1458-68. 2012
  3. doi request reprint Quality-of-life effects of prostate-specific antigen screening
    Eveline A M Heijnsdijk
    Department of Public Health, Erasmus Medical Center, P O Box 2040, 3000 CA Rotterdam, The Netherlands
    N Engl J Med 367:595-605. 2012
  4. pmc Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer
    E A M Heijnsdijk
    Department of Public Health, Erasmus MC, University Medical Centre Rotterdam, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Br J Cancer 101:1833-8. 2009
  5. pmc Treatment of local-regional prostate cancer detected by PSA screening: benefits and harms according to prognostic factors
    E M Wever
    Department of Public Health, Erasmus Medical Center, P O Box 2040, Rotterdam, 3000, CA, The Netherlands
    Br J Cancer 108:1971-7. 2013
  6. pmc To be screened or not to be screened? Modeling the consequences of PSA screening for the individual
    E M Wever
    Department of Public Health, Erasmus Medical Center, PO Box 2040, Rotterdam 3000 CA, The Netherlands
    Br J Cancer 107:778-84. 2012
  7. pmc Prediction of higher mortality reduction for the UK Breast Screening Frequency Trial: a model-based approach on screening intervals
    N T van Ravesteyn
    Department of Public Health, Erasmus MC, PO Box 2040, Rotterdam 3000 CA, The Netherlands
    Br J Cancer 105:1082-8. 2011
  8. pmc Population-based mammography screening below age 50: balancing radiation-induced vs prevented breast cancer deaths
    R de Gelder
    Erasmus MC, Department of Public Health, P O Box 2040, 3000 CA, Rotterdam, The Netherlands
    Br J Cancer 104:1214-20. 2011

Collaborators

Detail Information

Publications8

  1. pmc Breast density as indicator for the use of mammography or MRI to screen women with familial risk for breast cancer (FaMRIsc): a multicentre randomized controlled trial
    Sepideh Saadatmand
    Department of Surgery, Erasmus University Medical Centre, Rotterdam, Netherlands
    BMC Cancer 12:440. 2012
    ..The aim of the Familial MRI Screening Study (FaMRIsc) is to compare the efficacy of MRI screening to mammography for women with a familial risk. Furthermore, we will assess the influence of breast density...
  2. doi request reprint Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combined
    Eveline A M Heijnsdijk
    Department of Public Health, Erasmus MC, Rotterdam, The Netherlands
    Cancer Epidemiol Biomarkers Prev 21:1458-68. 2012
    ..Clinical observations suggest important differences in the natural history between breast cancers due to mutations in BRCA1 and BRCA2, potentially requiring different screening guidelines...
  3. doi request reprint Quality-of-life effects of prostate-specific antigen screening
    Eveline A M Heijnsdijk
    Department of Public Health, Erasmus Medical Center, P O Box 2040, 3000 CA Rotterdam, The Netherlands
    N Engl J Med 367:595-605. 2012
    ..However, the extent to which harms to quality of life resulting from overdiagnosis and treatment counterbalance this benefit is uncertain...
  4. pmc Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer
    E A M Heijnsdijk
    Department of Public Health, Erasmus MC, University Medical Centre Rotterdam, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Br J Cancer 101:1833-8. 2009
    ..Overdetection and overtreatment are substantial unfavourable side effects with consequent healthcare costs. In this study the effects of introducing widespread PSA screening is evaluated...
  5. pmc Treatment of local-regional prostate cancer detected by PSA screening: benefits and harms according to prognostic factors
    E M Wever
    Department of Public Health, Erasmus Medical Center, P O Box 2040, Rotterdam, 3000, CA, The Netherlands
    Br J Cancer 108:1971-7. 2013
    ..We quantified how the benefits and harms of immediate treatment vary according to the prognostic factors of clinical T-stage, Gleason score, and patient age...
  6. pmc To be screened or not to be screened? Modeling the consequences of PSA screening for the individual
    E M Wever
    Department of Public Health, Erasmus Medical Center, PO Box 2040, Rotterdam 3000 CA, The Netherlands
    Br J Cancer 107:778-84. 2012
    ..We estimated benefits and adverse effects of PSA screening for individuals who are deciding whether or not to be screened...
  7. pmc Prediction of higher mortality reduction for the UK Breast Screening Frequency Trial: a model-based approach on screening intervals
    N T van Ravesteyn
    Department of Public Health, Erasmus MC, PO Box 2040, Rotterdam 3000 CA, The Netherlands
    Br J Cancer 105:1082-8. 2011
    ..In this study, the trial is simulated in order to gain insight into the results of the trial and to predict the effect of different screening intervals on breast cancer mortality...
  8. pmc Population-based mammography screening below age 50: balancing radiation-induced vs prevented breast cancer deaths
    R de Gelder
    Erasmus MC, Department of Public Health, P O Box 2040, 3000 CA, Rotterdam, The Netherlands
    Br J Cancer 104:1214-20. 2011
    ..Because the radiation risk increases with lower exposure age, advancing the lower age limit may affect the balance between screening benefits and risks. The present study explores the benefit-risk ratio of screening before age 50...